$0.46
+0.04 (+8.58%)
Open$0.45
Previous Close$0.43
Day High$0.48
Day Low$0.42
52W High$1.43
52W Low$0.35
Volume—
Avg Volume25.5K
Market Cap3.07M
P/E Ratio—
EPS$-0.46
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,124.4% upside
Current
$0.46
$0.46
Target
$10.33
$10.33
$6.34
$10.33 avg
$12.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.14M | 2.03M | 2.27M |
| Net Income | 217.1K | 264.7K | 291.2K |
| Profit Margin | 10.1% | 13.0% | 12.9% |
| EBITDA | 334.0K | 340.0K | 365.4K |
| Free Cash Flow | 225.5K | 170.6K | 157.9K |
| Rev Growth | +23.7% | +5.3% | -4.1% |
| Debt/Equity | 1.01 | 0.93 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |